Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor

被引：125

作者：

Bhide, RS ^{[1
]}

Cai, ZW ^{[1
]}

Zhang, YZ ^{[1
]}

Qian, LG ^{[1
]}

Wei, D ^{[1
]}

Barbosa, S ^{[1
]}

Lombardo, LJ ^{[1
]}

Borzilleri, RM ^{[1
]}

Zheng, XP ^{[1
]}

Wu, LI ^{[1
]}

Barrish, JC ^{[1
]}

Kim, SH ^{[1
]}

Leavitt, K ^{[1
]}

Mathur, A ^{[1
]}

Leith, L ^{[1
]}

Chao, S ^{[1
]}

Wautlet, B ^{[1
]}

Mortillo, S ^{[1
]}

Jeyaseelan, R ^{[1
]}

Kukral, D ^{[1
]}

Hunt, JT ^{[1
]}

Kamath, A ^{[1
]}

Fura, A ^{[1
]}

Vyas, V ^{[1
]}

Marathe, P ^{[1
]}

D'Arienzo, C ^{[1
]}

Derbin, G ^{[1
]}

Fargnoli, J ^{[1
]}

机构：

[1] Bristol Myers Squibb, Pharmaceut Res Inst, Princeton, NJ 08543 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 07期

关键词：

D O I：

10.1021/jm051106d

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of substituted 4-(4-fluoro-1H-indol-5-yloxy)pyrrolo-[2,1-f][1,2,4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported. Structure-activity relationship studies revealed that a methyl group at the 5-position and a Substituted alkoxy group at the 6-position of the pyrrolo[2, 1-f][ 1,2,4]triazine core gave potent compounds. Biochemical potency, kinase selectivity, and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford BMS-540215 (12). which demonstrated robust preclinical in vivo activity in human tumor xenograft models. The L-alanine prodrug of 12, BMS-582664 (21), is currently under evaluation in clinical trials for the treatment of solid tumors.

引用

页码：2143 / 2146

页数：4

共 19 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2]

Beebe JS, 2003, CANCER RES, V63, P7301

[3]

Bhide R.S., Patent No. [2004009542, W02004009542]

[4] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents [J].

Bilodeau, MT ;

Fraley, ME ;

Hartman, GD .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) :737-745

[5] Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors [J].

Borzilleri, RM ;

Zheng, XP ;

Qian, LG ;

Ellis, C ;

Cai, ZW ;

Wautlet, BS ;

Mortillo, S ;

Jeyaseelan, R ;

Kukral, DW ;

Fura, A ;

Kamath, A ;

Vyas, V ;

Tokarski, JS ;

Barrish, JC ;

Hunt, JT ;

Lombardo, LJ ;

Fargnoli, J ;

Bhide, RS .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (12) :3991-4008

[6] Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo-[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors [J].

Borzilleri, RM ;

Cai, ZW ;

Ellis, C ;

Fargnoli, J ;

Fura, A ;

Gerhardt, T ;

Goyal, B ;

Hunt, JT ;

Mortillo, S ;

Qian, LG ;

Tokarski, J ;

Vyas, V ;

Wautlet, B ;

Zheng, XP ;

Bhide, RS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) :1429-1433

[7] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[8] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[9] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].

FOLKMAN, J .

NATURE MEDICINE, 1995, 1 (01) :27-31

[10] A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors:: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-α]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055 [J].

Gingrich, DE ;

Reddy, DR ;

Iqbal, MA ;

Singh, J ;

Aimone, LD ;

Angeles, TS ;

Albom, M ;

Yang, S ;

Ator, MA ;

Meyer, SL ;

Robinson, C ;

Ruggeri, BA ;

Dionne, CA ;

Vaught, JL ;

Mallamo, JP ;

Hudkins, RL .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) :5375-5388

← 1 2 →